3SOF

Profile Get Profile for:  

Point Therapeutics Inc.
155 Federal Street
Boston, MA 02110
Phone: 617-933-2130
Fax: 617-933-2131
Web Site: http://www.pointtherapeutics.com

DETAILS  
Index Membership: N/A
Sector: Healthcare
Industry: Medical Instruments & Supplies
Full Time Employees: 25


BUSINESS SUMMARY  
Point Therapeutics, Inc., a development stage biopharmaceutical company, develops a family of dipeptidyl peptidase (DPP) inhibitors for use in cancer, type 2 diabetes, and as vaccine adjuvants. Its lead product candidate, talabostat (PT-100), is a small molecule drug in phase 2 clinical trials. Talabostat would be used to inhibit the growth of malignant tumors and to support the reconstitution of the hematopoietic system. In addition, the company's portfolio includes two other DPP inhibitors in preclinical development: PT-630 for type 2 diabetes and PT-510 as a vaccine adjuvant. Point Therapeutics is based in Boston, Massachusetts.

Last news out on 12 December 2005....

Press Release Source: Point Therapeutics, Inc.


Point Therapeutics Announces Positive Interim Results at American Society of Hematology Annual Meeting from Phase 2 Talabostat Advanced Chronic Lymphocytic Leukemia Study
Monday December 12, 10:01 am ET


BOSTON--(BUSINESS WIRE)--Dec. 12, 2005--Point Therapeutics, Inc. (NASDAQ:POTP - News) presented positive interim results, exceeding the company's targeted 20% response rate, in their ongoing Phase 2 study of talabostat in combination with rituximab, a monoclonal antibody, in patients with advanced chronic lymphocytic leukemia (CLL) in a poster session at the American Society of Hematology Annual Meeting in Atlanta, GA.


This single-arm trial evaluates talabostat in combination with rituximab in up to 54 evaluable patients with advanced CLL who have failed fludarabine and/or rituximab. Thus far, 36 patients have entered the study and 31 meet criteria for evaluability (at least six days of talabostat with a post-baseline assessment by the investigator). 66.7% of the patients in the study are Rai Stage IV, the most advanced CLL patient population. Investigators have reported clinical responses in seven of 31 evaluable patients for an overall response rate of 22.5%. One of the seven responses is awaiting follow-up assessment to confirm the response. Five of the seven responses were observed in patients who had previously not responded to or had relapsed following prior treatment with rituximab-- suggesting that the addition of talabostat is providing additive activity. Importantly, three of these five patients had not only failed fludarabine and rituximab, but had also failed prior alemtuzumab treatment--the only approved agent in fludarabine failures.

Responses are evaluated based on the National Cancer Institute (NCI) Working Group Guidelines for CLL, which is the standard used in measuring treatment effectiveness in CLL. The most frequent adverse events are those commonly reported with rituximab, including nausea, fever, difficult/labored breathing, fatigue and itching, with the exception of peripheral edema, which is associated with talabostat. The trial is continuing to enroll and all patients will continue to be followed for durability of response, progression-free survival and survival.

"I am very pleased that we are continuing to see positive results in this trial," said Dr. Khuda Dad Khan, a lead investigator in Point's CLL trial at Indiana Oncology Hematology Consultants. "Patients who are refractory to fludarabine are among the toughest patients to treat because of the advanced stage of disease and minimal treatment options. The only approved treatment option for these advanced patients is often difficult to tolerate, and rituximab is used empirically as an alternative to this treatment. The fact that the addition of talabostat to rituximab is demonstrating positive results-- especially in patients who had failed rituximab in the past--is very exciting. The toxicity profile is low and because talabostat is orally administered, it's easy for patients to take at home--a convenience they like. I believe talabostat has the potential to become an important treatment option for advanced CLL, especially for patients who have exhausted other choices," concluded Dr. Khan.

"These positive interim results in our CLL trial continue a very productive fourth quarter for Point," said Don Kiepert, President and CEO of Point Therapeutics, Inc. "In October, we initiated our first Phase 3 trial in non-small cell lung cancer after a successful End-of-Phase 2 meeting with the FDA. Over the last two months, we have presented positive results from three of our Phase 2 talabostat trials at major scientific conferences--non-small cell lung cancer, single-agent melanoma, and now these latest positive findings in CLL. Earlier this month, we also completed a follow-on offering, raising net proceeds of $25.5 million. We look forward to continuing this momentum in the first quarter of 2006 and anticipate making a decision about next steps for our Phase 2 CLL trial during this timeframe," concluded Kiepert.

This trial is partially funded through an Orphan Products Grant from the Food and Drug Administration, Office of Orphan Products Development. Orphan Products Development grants are awarded by the Food and Drug Administration to encourage clinical development of products for use in rare diseases or conditions, usually defined as affecting fewer than 200,000 people in the United States.

About Point Therapeutics, Inc.:

Point is a Boston-based biopharmaceutical company developing a family of dipeptidyl peptidase (DPP) inhibitors for use in cancer, type 2 diabetes and as vaccine adjuvants. Point is currently studying its lead product candidate, talabostat, in a Phase 3 trial in NSCLC. Point is also studying talabostat in several Phase 2 trials, including as a single-agent in metastatic melanoma, in combination with cisplatin in metastatic melanoma, in combination with rituximab in advanced chronic lymphocytic leukemia, and in combination with gemcitabine in metastatic pancreatic cancer. In addition, Point's portfolio includes two other DPP inhibitors in preclinical development--PT-630 for type 2 diabetes, and PT-510 as a vaccine adjuvant.

Certain statements contained herein are not strictly historical and are "forward looking" statements as defined in the Private Securities Litigation Reform Act of 1995. This information includes statements with respect to the company's clinical development programs, the timing of initiation and completion of its clinical trials, and the potential of talabostat to become an important treatment for chronic lymphocytic leukemia cancer. Forward-looking statements are statements that are not historical facts, and can be identified by, among other things, the use of forward-looking language, such as "believes," "feels," "expects," "may," "will," "should," "seeks," "plans," "schedule to," "anticipates" or "intends" or the negative of those terms, or other variations of those terms of comparable language, or by discussions of strategy or intentions. A number of important factors could cause actual results to differ materially from those projected or suggested in the forward looking statement, including the risk factors described in Point's quarterly report on Form 10-Q for the quarter ended September 30, 2005 and from time to time in Point's periodic and other reports filed with the Securities and Exchange Commission.

Contact:
Point Therapeutics, Inc.
Sarah Cavanaugh, 617-933-7508
Director, Corporate Communications

--------------------------------------------------------------------------------
Source: Point Therapeutics, Inc.

Indicator have turned up. RSI moving through 50.
A penny above the 50-dma.
Complete spec....the chart says buy.

Support @ $3.39...3.15...3.07
Resistance @ $3.61...3.94...4.05

Technicals
Percentage Gainer

Last Price Quote is:
13.54%above 13-day EMA

Fundamentals
Key Data:
Market Cap (M): $81.06 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: 03/09/2006
Last Analyst Rating: Sector Perform

Well...well...well 
She dropped like a hot rock from January 2006...
Now look at her today !
You snooze...You lose !!!


52wk Range: 0.03 - 1.72
Volume: 49,945,014
Avg Vol (3m): 1,592,900

Technicals
Record Volume
Most Actives
Percentage Gainer

Last Price Quote is:
530.22%above 13-day MA
327.64%above 50-day MA
RS Rating: N/A 

Fundamentals
Key Data:
Market Cap (M): $1.69 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: N/A
Last Analyst Rating: Sector Perform

Below are the 6 month and 3 year charts.......

Press Release Source: Point Therapeutics, Inc.


DARA BioSciences and Point Therapeutics Announce Merger Plans
Wednesday October 10, 8:00 am ET


RALEIGH, N.C. & WELLESLEY HILLS, Mass.--(BUSINESS WIRE)--DARA BioSciences(TM), a privately held development-stage pharmaceutical company, and Point Therapeutics, Inc. (NASDAQ: POTP - News), a biopharmaceutical company, today announced that they have entered into a definitive agreement to merge.


Pursuant to the merger agreement, DARA will merge with a subsidiary of Point, with DARA surviving as a wholly-owned subsidiary of Point. After giving effect to the merger, DARA stockholders will hold 96.4% of Point's outstanding shares of common stock on a fully-diluted basis, and Point will change its name to DARA BioSciences, Inc. and be based in Raleigh. The acquisition is intended to be a tax-free reorganization under Section 368(a) of the Internal Revenue Code and is expected to close in the first quarter of 2008.

The combined company plans to evaluate and prioritize its potential research and development programs. DARA and Point's combined R&D assets for the development of therapeutics are focused in the areas of metabolic diseases, including Type 2 diabetes, neuropathic pain, dermatologic disorders, and oncology. A recently signed license agreement with Bayer Pharmaceuticals grants DARA exclusive worldwide rights to a series of patents and compounds for the treatment of metabolic diseases, including Type 2 diabetes and dyslipidemia, expanding DARA's current product candidate pipeline for metabolic diseases. DARA is also developing a novel therapeutic candidate for the treatment of chronic neuropathic pain in cancer patients, a program that is currently in a Phase 2 clinical trial.

Commenting on the announced merger plans, Richard A. Franco, Sr., DARA's President and Chief Executive Officer, stated, "All parties involved believe this to be a logical and productive course of action given the potential synergies of combining Point and DARA. We believe this transaction provides an exciting opportunity for the stockholders of both companies to realize value and liquidity from this combination."

"We are excited about the opportunity to merge with DARA," said Don Kiepert, Point's Chairman and President. "The combination of Point and DARA will give our stockholders an opportunity to retain an equity interest in a stronger company with a broad and attractive portfolio of potential products."

Point and DARA believe that the proposed merger will qualify as a "reverse merger" under NASDAQ Marketplace Rule 4340. As a result, although Point's common stock is currently listed on NASDAQ, DARA intends to file an initial listing application and satisfy all requirements for initial listing, subject to the completion of the merger and NASDAQ approval. As previously announced on September 17, 2007, Point received a determination letter from the staff of The NASDAQ Stock Market indicating that Point's securities are subject to potential delisting from NASDAQ. The staff determination was based on the fact that Point does not currently meet the $1 minimum share price requirement for continued listing on NASDAQ and that Point's recent cessation of its clinical and research operations renders Point a "public shell," or non-operating company in the opinion of the staff. Point has requested a hearing before a NASDAQ Listing Qualifications Panel and intends to seek continued listing of its common stock pending the completion of the merger, subject to NASDAQ approval.

About Point Therapeutics, Inc.

Point Therapeutics, Inc. is a biopharmaceutical company which has studied its lead product candidate, talabostat, in a number of human clinical trials in late-stage cancers. Recent interim clinical results caused Point's Independent Data Monitoring Committee to recommend stopping Point's most advanced clinical trials, two Phase 3 talabostat studies for patients in advanced non-small cell lung cancer. Subsequently, the talabostat clinical development program was put on clinical hold by the FDA. Point has also studied talabostat in several Phase 2 trials, including as a single-agent and in combination with cisplatin in metastatic melanoma, in combination with rituximab in advanced chronic lymphocytic leukemia, and in combination with gemcitabine in Stage IV pancreatic cancer. Due to cash limitations, Point is not currently funding any research or clinical operations.

About DARA BioSciences, Inc.

DARA BioSciences(TM), Inc. is a Raleigh, North Carolina-based development-stage pharmaceutical company that acquires promising therapeutic molecules and medical technologies directly. DARA focuses its therapeutic development efforts on small molecules from late preclinical development through phase 2 clinical trials. DARA is developing a portfolio of therapeutic candidates for neuropathic pain, metabolic diseases including Type 2 diabetes, and dermatological disorders.

For more information, please contact DARA at 919-872-5578 or visit our web site at www.darabiosciences.com.

Please Note: This press release contains forward-looking statements regarding future events. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include receipt of stockholder and regulatory approvals and other risks that the transaction might not close, integration of the two companies, risks related to the potential lack of a liquid market for the company's stock, reliance on key employees, risks of testing of drug candidates for proof of principle, risks of regulatory review and clinical trials, competition, market acceptance for approved products, if any, and intellectual property risks.

Additional Information

In connection with the merger between DARA and Point, Point intends to file with the SEC a registration statement on Form S-4, containing a joint proxy statement/prospectus and other relevant materials. INVESTORS AND SECURITY HOLDERS OF DARA AND POINT ARE URGED TO READ THE JOINT PROXY STATEMENT/PROSPECTUS AND THE OTHER RELEVANT MATERIALS WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT DARA, POINT AND THE MERGER. The joint proxy statement/prospectus and other relevant materials (when they become available), and any other documents filed by Point with the SEC, may be obtained free of charge at the SEC's web site at www.sec.gov. In addition, investors and security holders may obtain free copies of the documents (when they are available) filed with the SEC by Point by directing a request to: Point Therapeutics, Inc., 70 Walnut Street, Wellesley Hills, MA 02481, Attention: Investor Relations.

Point and its executive officers and directors may be deemed to be participants in the solicitation of proxies from the stockholders of Point in favor of the merger. Information about the executive officers and directors of Point and their ownership of Point common stock is set forth in Point's Annual Report on Form 10-K/A filed with the SEC on April 30, 2007. Investors and stockholders may obtain more detailed information regarding the direct and indirect interests of DARA, Point and their respective executive officers and directors in the merger by reading the joint proxy statement/prospectus regarding the merger when it becomes available.



Contact:
DARA BioSciences, Inc.
John C. Thomas, Jr., 919-872-5578
Chief Financial Officer
or
Point Therapeutics, Inc.
Michael P. Duffy, 781-239-7503
Corporate Secretary
or
Lynn H. Morris, 919-872-5578
Sr. Manager
Investor Relations & Corporate Operations

--------------------------------------------------------------------------------
Source: Point Therapeutics, Inc.

AP
DARA Buying Point Therapeutics
Wednesday October 10, 8:56 am ET 
Biotechnology Company Point Therapeutics to Be Bought by DARA BioSciences


BOSTON (AP) -- Biotechnology company Point Therapeutics Inc. said Wednesday it is being bought by privately held DARA BioSciences for an undisclosed amount.
DARA shareholders will hold 96.4 percent of Point Therapeutics stock after the buyout. Point will change its name to DARA BioSciences Inc. The deal is expected to close during the first quarter of 2008.

The acquisition is intended to be a tax-free reorganization under Internal Revenue Code rules. The companies also expect the deal to be considered a "reverse merger" by Nasdaq, and DARA will file for initial listing on the exchange.

Point Therapeutics currently faces being delisted from the Nasdaq, because it does not meet the exchange's $1 minimum share price requirement.

Shares of Point Therapeutics gained 11 cents at 15 cents in premarket trading after closing at 4 cents Tuesday.

A nice looking bounce this morning off a
61.8% Fibonacci retracement.

52wk Range: 0.03 - 1.72
Volume: 2,559,593
Avg Vol (3m): 1,899,500

Technicals
Most Actives
Percentage Gainer

Last Price Quote is:
103.15%above 13-day MA
213.26%above 50-day MA
RS Rating: N/A 

Fundamentals
Key Data:
Market Cap (M): $9.89 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: N/A
Last Analyst Rating: Sector Perform

 

Moving in the Pre-Market.......

POINT THERAPEUTICS (NasdaqCM:POTP)   

Pre-Market: 0.43  0.17 (+65.47%) as of 9:00AM ET on 10/17/07

Press Release Source: DARA BioSciences, Inc.


DARA BioSciences and Bayer Pharmaceuticals Corporation Sign Exclusive License Agreement
Wednesday October 17, 7:00 am ET


RALEIGH, N.C. and WEST HAVEN, Conn., Oct. 17 /PRNewswire/ -- DARA BioSciences, Inc. and Bayer Pharmaceuticals Corporation (BPC), a U.S. subsidiary of Bayer HealthCare AG signed a license agreement granting DARA BioSciences exclusive worldwide rights to a series of patents and compounds for the treatment of metabolic diseases, in particular type 2 diabetes and dyslipidemia. Lead compounds are in later preclinical development.


Under the terms of the agreement DARA BioSciences will develop and commercialize products while Bayer will receive an upfront payment, milestone payments and royalties during the development and commercialization. In addition, Bayer has certain rights to commercialize products emanating from this development program.

Richard A. Franco, Sr., President and Chief Executive Officer, stated, "DARA BioSciences' licensing-in of the Bayer technology demonstrates our commitment to exploring new alternatives in the treatment of metabolic diseases including diabetes. This transaction also demonstrates our continuing success in executing our strategy to identify new opportunities in order to expand and diversify our product portfolio. We look forward to the opportunity to work with Bayer."

The WHO estimates that globally over 170 million people have diabetes. Type 2 diabetes accounts for 90% to 95% of all cases of diabetes. Worldwide the costs associated with treating diabetes and its complications are estimated to exceed $200 billion a year. By 2030 the prevalence of diabetes is predicted to double, driven by adverse lifestyle changes which have seen an explosion in the incidence of obesity, a risk factor for type 2 diabetes. Worldwide, diabetes is a huge and growing problem for which new treatments are needed.

About Bayer HealthCare

The Bayer Group is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Bayer HealthCare, a subsidiary of Bayer AG, is one of the world's leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Diabetes Care and Pharmaceuticals divisions. Bayer HealthCare's aim is to discover and manufacture products that will improve human and animal health worldwide. Find more information at www.bayerhealthcare.com.

About DARA BioSciences, Inc.

DARA BioSciences(TM), Inc. ("DARA") is a Raleigh, North Carolina-based development-stage pharmaceutical company that acquires promising therapeutic molecules and medical technologies directly or through investment in established companies. DARA focuses its therapeutic development efforts on small molecules from late preclinical development through phase 2 clinical trials. DARA is developing a portfolio of therapeutic candidates for neuropathic pain, metabolic diseases including type 2 diabetes, and dermatological disorders. On October 10, 2007, DARA announced an agreement to merge with Point Therapeutics, Inc. (Nasdaq: POTP - News).

For more information please contact DARA at 919-872-5578 or visit our web site at www.darabiosciences.com.

Please Note: This press release contains forward-looking statements regarding future events. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include risks of testing of drugs for proof of principle, risks of regulatory review and clinical trials, competition, market acceptance for approved products, if any, and intellectual property risks.

--------------------------------------------------------------------------------
Source: DARA BioSciences, Inc.

Price is going to pop again and again. Look at the chart. Here is why its going up:

Stock is POTP---POINT THERAPEUTICS (but read on>>there is a surprise)

Here is the rub....you're not investing in this company

There is a reverse merger that is happening with the below company--DARA BioSciences

This is where you want to do your research--http://www.darabiosciences.com/

It's late...so here is the skinny

First read this----

Founder and Co-Chairman of the Board
Nationally featured by such renowned publications as The Wall Street Journal and Fortune magazine as an authority on his industries, Mr. Gorlin founded several highly successful biotechnology and pharmaceutical companies in the last 25 years. Those companies include Hycor Biomedical, Inc., Theragenics Corporation, CytRx Corporation, Medicis Pharmaceutical Corporation, EntreMed, Inc., Surgi-Vision, Inc., DARA BioSciences, Inc., and Medivation, Inc.

This is the guy that Founded and leads the company...very important you remeber him and google him

THIS GUY IS THE REAL DEAL

Google all the companies in the above paragraph...as you can see all are successful..some INCREDIBLY so

Now he has this company Dora...and he feels this is the right time to take it public

He finds a company that is virtually a shell..on the verge of BK

He does (doing) a reverse merger (here is a link to find some quick facts and advantages ESPECIALLY IF YOU BUY A COMPANY WITH LOSSES (CAN YOU SAY LOSS CARRYFORWARD ;>) http://en.wikipedia.org/wiki/Reverse_merger

Oh did I mention that POTP..this stock is on NASD (not OTC)
and Steve..sorry Mr Gorlin...is VERY wealthy..has (as you can see) GREAT experience taking and running publicly traded companies

One of his holdings is one of his companies MDVN..here is SEC excerpt

a) The aggregate number of shares of the Common Stock beneficially owned by the Reporting Person is 2,818,607, which represents beneficial ownership of the Reporting Person of approximately 23.6% of the Common Stock

Worth a cool 63MILLION in that co ALONE

OH did I meniton MDVN has a 600MILLION market cap and NEGATIVE revs..never made a penny and only 27M sharesOS!!!!!

Why is that significant...BEACUSE IT PROVES HE HAS THE FUNDING TO CARRYOUT BUS GROWTH With no dilution and HE HAS SOME SERIOUS CONNECTIONS AND MARKET TRUSTS HIM TO BRING HOME A WINNER

OK---Here is my summary

Reverse merger to go through Next Jan (2.5 months)
He wants to keep the stock listed on Nas (so price to keep it on needs to be over 1.00 and I am sure he wants it much higher)

Instituions know and love this guy (check out MDVN) http://finance.yahoo.com/q/mh?s=MDVN

the stock just rose alittle over 1000% BUT THIS IS A REVERSE MERGER...not like you are buying into a stock that went up on good news...this is more like owning ERF and Motorola buys them..so don;t let the increase fool you AND EXPECT A BIG DOWN TREND

TOday on level 2, at then end of the day there was over a 1 Million buy order at .36..stock rose to .37 on that last minute pressure and is in .38 in after hours (which I really don't trust afetr hours too much..but something to note)

After the hUge increase you would expect a down day...and it was most fo the day..until the end..pretty incredible

I am looking for .30-.50 range...then as it gets nearer to Jan and or if there is some progression news on the merger...we climb to the 1.00 plus area

Then who knows

Only 40 Million shares on this

And last but not least---DoRa just got an announcement (on Oct 10 in the SEC filing but just released in a PR on the 17th as they just announced the merger on the 10th)---they just got a lisc agreement with ...with...I won't ruin the surprise..here is the link http://biz.yahoo.com/prnews/071017/clw008b.html?.v=1

i HAVE BEEN RIDING THIS STOCK AND HAVE BEEN BUYIN BIG TODAY AND LOOK TO DO SO

ENJOY...and DO YOUR OWN RESEARCH!!!!

lylakaveli,
This new thread you created on this pick has been merged.
Moved from where you had posted on The Penny Stock Picking.


"POTP" Threads have been Merged.
Please use the search before starting new threads on a Stock Pick.
Chances are a thread already exist.
So why not post whatever you have to comment about on that pick to that thread.
"Simplicity" My fellow traders.                                                       
All history on a stock pick in 1 thread is awesome.                                                          
Just trying to get threads together,so we don't have a numerous amount floating around on the same stock.                                                     
Thank You....and good luck with all your trades....make some $$$             

POTP prime for buying today.
Check it yourself.
MACD indicates heavy accumulation, big money sneaking in gradually. Poor volume on this day of correction. Not even half of Fridays bull run. Good sign.
Trading above its 50ma and 50ema.
%k is above the %d in the stochastics which currently reading 50%, neither overbought nor oversold.

This is a great risk reward entry currently for POTP because we're talking about a run up to $1 before the merger. Only risk the money you're able to part with and you might be nicely surprised because each time the big boys decide to take a bite, the stock gaps up

It is about to pop 10 cents. Just watch in a couple of days

Notice the behavior of the stock when its gets pulled down. The volume is very weak on down days because nobody wants to sell except for a few profit takers. MM's are trying their best to depress the press so as to get in while the getting is good. There is underlying accumulation as the MACD shows clearly.
Note this one last thing, for the last couple of weeks, the price will gap up after a couple days of down trading on low volume. And the volumes on those up days to say the least, is incredible. This stock will be at 50 cents plus by the end of the week.
Currently a very strong buy. Just watch the action tomorrow morning.

After hours trading of almost 5%! Here is the gap up and then zoom to the moon. Take a look at the chart and you will see this behavior.